Research digest / about
About Tesa Direct.
A reading bench for the tesamorelin trial record, read straight off the page — what the studies measured, and where the one approved indication ends and off-label research begins.
What this site is
Tesa Direct is a reading bench for the peer-reviewed research literature on tesamorelin: it gathers what the trials measured and lays it out in plain words. No clinic or pharmacy stands behind it, nobody here sees patients or writes prescriptions, and there is nothing on offer to buy — the pages read the science and cite it, they do not treat, diagnose, or advise.
The approach is deliberately flat and plain: state what the trials measured, carry every figure back to its study, and mark the regulatory scope precisely — the one approved HIV-lipodystrophy indication as approved, every other use as off-label. The site is an information board for the published record, not a course of treatment and not a place to obtain anything.
The word "direct" in the domain names a posture, not a service. It means reading the literature without a sales layer between you and the evidence — a plain, no-nonsense register. It does not imply that this site dispenses, supplies, or routes anyone to tesamorelin.
Is Tesamorelin FDA Approved?
Yes, but the scope is narrow and the precision matters. Tesamorelin was approved by the FDA in 2010 (NDA 022505) to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. That is the only indication for which it is approved.
Every other use is off-label and not FDA-approved: general or cosmetic fat loss, anti-aging, GH optimization, performance use, and non-HIV NAFLD/MASLD all fall outside the approval. So the accurate one-line answer is neither "approved" without qualification nor "not approved" — it is approved for one HIV-related indication and off-label for everything else. This site holds that line throughout, and it is the single most important fact about the compound's regulatory status. For sport, tesamorelin is additionally prohibited under the WADA Prohibited List category S2.
Is tesamorelin FDA approved?
Yes, but narrowly: tesamorelin was approved in 2010 (NDA 022505) only to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. Every other use, including general or cosmetic fat loss, anti-aging, and performance, is off-label and not FDA-approved.
How we handle the evidence
Three rules govern every page. First, no claim appears without a source: the visceral-fat numbers come from the pivotal trials [1][2], the mechanism from the healthy-men and PK-PD studies [4][10], the hepatic-fat data from the JAMA trial [6], and the safety record from the type-2-diabetes trial and the LiverTox monograph [5][7]. Second, the approved indication is kept distinct from investigational and off-label research at all times. Third, we give no human-dosing instructions — doses appear only as research context, framed as what was studied in which population. The full reference list carries every source with its DOI or PubMed link.